Prokidney (PROK) Common Equity (2021 - 2026)

Prokidney (PROK) has reported Common Equity for 6 consecutive years, with -$883.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 11.87% year-over-year to -$883.5 million in Q2 2026; TTM through Jun 2026 was -$883.5 million, a 11.87% increase from a year earlier, with the FY2025 full-year figure at -$1.0 billion, down 1.63% from the prior year.
• Common Equity was -$883.5 million for Q2 2026 at Prokidney, up from -$1.0 billion in the prior quarter.
• Over five years, Common Equity peaked at $20.2 million in Q1 2022 and troughed at -$1.6 billion in Q1 2023.
• A 5-year average of -$958.7 million and a median of -$1.0 billion in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 101661.03% in 2022 and slumped 20327.23% in 2023, its largest moves.
• Over 5 years, Common Equity stood at -$1.1 billion in 2022, then retreated by 0.62% to -$1.1 billion in 2023, then advanced by 9.83% to -$995.0 million in 2024, then fell by 1.63% to -$1.0 billion in 2025, then climbed by 12.63% to -$883.5 million in 2026.
• The last three Common Equity figures came in at -$883.5 million (Q2 2026), -$1.0 billion (Q1 2026), and -$1.0 billion (Q4 2025), per Business Quant data.